Literature DB >> 6467858

Extended treatment of primary osteoporosis by sodium fluoride combined with 25 hydroxycholecalciferol.

D Kuntz, P Marie, B Naveau, B Maziere, M Tubiana, A Ryckewaert.   

Abstract

Nineteen patients suffering from primary osteoporosis, all having at least one vertebral collapse, initially received 50 mg of sodium fluoride alone per day for 6-18 months. Subsequently fluoride was associated with 25-50 micrograms of 25 OH cholecalciferol (calcifediol) per day for 6-18 months in 12 of these patients and 9 were treated for 31-58 months. As control group, 9 patients were given placebo for 6-18 months. The effect of the treatment was assessed by three methods: 1) the metacarpal index (MI) determined by radiogrammetry, 2) the calcium content of the hand bone (Ca) measured by local neutron activation, 3) the iliac bone histomorphometry. MI and (Ca) did not change significantly at any time in any group. In each group there was a significant increase in trabecular bone volume, osteoid volume, osteoid surfaces and a significant decrease in mineralization fronts. On the other hand, the changes in osteoblastic surfaces, osteoclastic surfaces, number of osteoclasts/mm2 were not significant in any group. No change was observed in the placebo group. These data suggest that the increase in the trabecular volume of fluorided bone is mainly due to the increase in osteoid which itself is due to a bone mineralization defect despite the association of calcifediol. This is probably one of the reasons why (Ca) does not change significantly.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6467858     DOI: 10.1007/bf02030747

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  15 in total

1.  [Histomorphometric study of pelvic-crest biopsies during long-term fluoride treatment of osteoporosis (author's transl)].

Authors:  C Hauswaldt; C Fuchs; R D Hesch; J Köbberling; K O Unger
Journal:  Dtsch Med Wochenschr       Date:  1977-08-19       Impact factor: 0.628

2.  Effect of variations in calcium intake on the skeleton of fluoride-fed kittens.

Authors:  J M Burkhart; J Jowsey
Journal:  J Lab Clin Med       Date:  1968-12

3.  Determination of fluoride in mineralized tissues using the fluoride ion electrode.

Authors:  H G McCann
Journal:  Arch Oral Biol       Date:  1968-04       Impact factor: 2.633

4.  Three-year changes in bone mineral mass of postmenopausal osteoporotic patients based on neutron activation analysis of the central third of the skeleton.

Authors:  J E Harrison; K G McNeill; W C Sturtridge; T A Bayley; T M Murray; C Williams; C Tam; V Fornasier
Journal:  J Clin Endocrinol Metab       Date:  1981-04       Impact factor: 5.958

5.  A quantitative histological study on bone formation in human cancellous bone.

Authors:  W A Merz; R K Schenk
Journal:  Acta Anat (Basel)       Date:  1970

6.  Treatment of osteoporosis with fluoride, calcium, and vitamin D.

Authors:  D Briancon; P J Meunier
Journal:  Orthop Clin North Am       Date:  1981-07       Impact factor: 2.472

7.  [Multiple bony fissures during treatment of osteoporosis with sodium fluoride].

Authors:  T Glimet; D Kuntz; M C de Vernejoul; A Ryckewaert
Journal:  Rev Rhum Mal Osteoartic       Date:  1980-10

8.  [Histological study of bone in osteoporotic patients receiving prolonged treatment with sodium fluoride].

Authors:  A Ryckwaert; D Kuntz; J P Teyssedou; S T Chot; P Bordier; D Hioco
Journal:  Rev Rhum Mal Osteoartic       Date:  1972-10

9.  [Fluorine osteosis caused by a very long-term niflumic acid treatment in 2 cases of rheumatoid arthritis].

Authors:  A Prost; H L Boiteau; F Gaillard; J P Hamelin; N Carlier; F Rossel-Renac
Journal:  Rev Rhum Mal Osteoartic       Date:  1978-12

10.  Effect of the fluoride/calcium regimen on vertebral fracture occurrence in postmenopausal osteoporosis. Comparison with conventional therapy.

Authors:  B L Riggs; E Seeman; S F Hodgson; D R Taves; W M O'Fallon
Journal:  N Engl J Med       Date:  1982-02-25       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.